Andrew Brunner, MD, of Massachusetts General Hospital, Boston, MA, describes the treatment protocol for higher risk myelodysplastic syndromes (MDS). Despite the absence of new drug approvals for the treatment of high-risk MDS, greater understanding into the molecular behavior of the disease and its dynamics has enabled the development of optimal treatment regimens. Dr Brunner explains the first step is the evaluation of transplant candidacy whereby patients ineligible for transplant undergo treatment primarily with hypomethylating agents. Additionally, patients with mutations such as FLT3 or IDH1/2 mutations can be put on mutation-specific treatment regimens earlier in the algorithm. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Негізгі бет The treatment protocol for higher risk MDS
Пікірлер